TY - JOUR
T1 - Efficacy of primary chemoprophylaxis against Pneumocystis carinii pneumonia during the first year of life in infants infected with human immunodeficiency virus type 1
AU - Rigaud, Mona
AU - Pollack, Henry
AU - Leibovitz, Eugene
AU - Kim, Kimi
AU - Persaud, Deborah
AU - Kaul, Aditya
AU - Lawrence, Robert
AU - John, David Di
AU - Borkowsky, William
AU - Krasinski, Keith
N1 - Funding Information:
Pneumocystis carinii pneumonia is the most commonly diagnosed opportunistic infection of infants and children with human immunodeficiency virus-1 infection, accounting for 62% of acquired immunodeficiency syndrome diagnosed in Supported by a grant from the National Institute of Drug Abuse (1 RO1 DA04791), AIDS Clinical Treatment Group (U01A 127553), and a grant from the Shubert Foundation. Submitted for publication Dec. 29, 1993; accepted April 7, 1994. Reprint requests: Mona Rigaud, MD, Department of Pediatrics, New York University Medical Center, 550 First Ave., New York, NY 10016. Copyright | 1994 by Mosby-Year Book, Inc. 0022-3476/94/$3.00 + 0 9/25/56498 the first 12 months of life and 37% of all cases of pediatric acquired immunodeficiency syndrome.i, 2 Between 13% and 21% of infected infants younger than 1 year of age have been reported to have PCP. 3 The mortality rate in this age group
PY - 1994/9
Y1 - 1994/9
N2 - To evaluate the efficacy of primary chemoprophylaxis in preventing Pneumocystis carinii pneumonia (PCP) in infants with perinatal human immunodeficiency virus-1 infection during the first year of life, we conducted a retrospective chart review of infants with human immunodeficiency virus-1 infection born at New York University Medical Center-Bellevue Hospital Center, in New York. Between March 1989 and March 1993, 24 infants received primary chemoprophylaxis with trimethoprim-sulfamethoxazole in the first year of life and 24 infants did not receive primary prophylaxis. The CD4+ T-lymphocyte counts in the two groups did not differ during the first year of life. The median age at the time of initiation of prophylaxis was 3 months, and the average duration of prophylaxis was 5.5 months. Among the infants who had not recelved prophylaxis, five cases of PCP were diagnosed at a median age of 5 months; in contrast, no cases of PCP were observed in the infants receiving prophylaxis (log-rank test, p=0.017). The probability of surviving after 1 year of age was 92% for the children who recelved prophylaxis and 74% for those who did not (long-rank test, p=0.035). These data indicate that chemoprophylaxis is highly effective in preventing primary PCP and improving survival time in infants with human immunodeficiency virus-1 infection.
AB - To evaluate the efficacy of primary chemoprophylaxis in preventing Pneumocystis carinii pneumonia (PCP) in infants with perinatal human immunodeficiency virus-1 infection during the first year of life, we conducted a retrospective chart review of infants with human immunodeficiency virus-1 infection born at New York University Medical Center-Bellevue Hospital Center, in New York. Between March 1989 and March 1993, 24 infants received primary chemoprophylaxis with trimethoprim-sulfamethoxazole in the first year of life and 24 infants did not receive primary prophylaxis. The CD4+ T-lymphocyte counts in the two groups did not differ during the first year of life. The median age at the time of initiation of prophylaxis was 3 months, and the average duration of prophylaxis was 5.5 months. Among the infants who had not recelved prophylaxis, five cases of PCP were diagnosed at a median age of 5 months; in contrast, no cases of PCP were observed in the infants receiving prophylaxis (log-rank test, p=0.017). The probability of surviving after 1 year of age was 92% for the children who recelved prophylaxis and 74% for those who did not (long-rank test, p=0.035). These data indicate that chemoprophylaxis is highly effective in preventing primary PCP and improving survival time in infants with human immunodeficiency virus-1 infection.
UR - http://www.scopus.com/inward/record.url?scp=0027989439&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027989439&partnerID=8YFLogxK
U2 - 10.1016/S0022-3476(05)83301-3
DO - 10.1016/S0022-3476(05)83301-3
M3 - Article
C2 - 7915306
AN - SCOPUS:0027989439
SN - 0022-3476
VL - 125
SP - 476
EP - 480
JO - The Journal of Pediatrics
JF - The Journal of Pediatrics
IS - 3
ER -